AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|AAPL316.22+2.83 (+0.90%) ▲|ABBV249.91-2.83 (-1.12%) ▼|ABT94.40-0.78 (-0.82%) ▼|ACN139.06+3.50 (+2.58%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT165.00-0.04 (-0.02%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.11-1.84 (-0.82%) ▼|BAC59.25+0.95 (+1.63%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.68+29.34 (+2.96%) ▲|BMY57.94+0.40 (+0.70%) ▲|BNY152.26+2.12 (+1.41%) ▲|BRK-B495.45+0.66 (+0.13%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.39-9.69 (-1.02%) ▼|CL91.01-2.03 (-2.18%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.10+8.15 (+4.25%) ▲|COP108.02-2.70 (-2.44%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.50-4.08 (-2.45%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.81-1.66 (-1.59%) ▼|CVX174.05-1.92 (-1.09%) ▼|DE592.90-3.84 (-0.64%) ▼|DHR195.98+5.21 (+2.73%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.26-1.53 (-1.21%) ▼|EMR137.80+1.32 (+0.97%) ▲|FDX310.84+1.08 (+0.35%) ▲|GD374.60+0.29 (+0.08%) ▲|GE359.04+3.01 (+0.85%) ▲|GEV1,075.26+4.27 (+0.40%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.54%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,055.97+26.33 (+2.56%) ▲|HD338.73+2.52 (+0.75%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.30-6.75 (-2.23%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.10-4.30 (-1.63%) ▼|JPM335.47+4.85 (+1.47%) ▲|KO82.63-0.77 (-0.92%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.95+1.12 (+0.09%) ▲|LMT518.26-9.70 (-1.84%) ▼|LOW213.00+0.15 (+0.07%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.20+4.21 (+0.81%) ▲|MCD276.49-1.76 (-0.63%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.39+0.38 (+0.46%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.34+0.64 (+0.41%) ▲|MO71.59-1.22 (-1.68%) ▼|MRK125.07-0.92 (-0.73%) ▼|MS222.13+4.06 (+1.86%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.10-0.34 (-0.39%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.78-0.11 (-0.26%) ▼|NOW108.84+1.06 (+0.98%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.22+3.73 (+2.66%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.85-1.55 (-1.04%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.17-5.90 (-3.15%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.91+0.21 (+0.21%) ▲|SO95.17-1.21 (-1.26%) ▼|SPG219.71+0.62 (+0.28%) ▲|T21.04-0.08 (-0.38%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.02%) ▲|UNH431.68+6.08 (+1.43%) ▲|UNP285.04+4.10 (+1.46%) ▲|UPS110.74+0.80 (+0.73%) ▲|USB61.90+0.90 (+1.48%) ▲|V348.20+0.67 (+0.19%) ▲|VZ42.24-0.21 (-0.49%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.46-3.67 (-2.60%) ▼|
23.7 C
New York
Friday, July 10, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

From Campus to Cockpit: Chula-Thai Airways Unite for a Future-Ready Thailand

BANGKOK, June 16, 2025 /PRNewswire/ -- Chulalongkorn University and Thai Airways International Public Company Limited have signed a memorandum of understanding (MoU) to promote and...

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Bid Farewell to Investment Confusion: Theinvestmedia.com, with Eight Years of Expert Experience, Builds Hong Kong’s Most Trusted Platform for Account Opening Offer Comparisons and...

HONG KONG, June 16, 2025 /PRNewswire/ -- today announced its goal to become Hong Kong's leading platform for comparing account opening offers and...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Readout – Prime Minister Carney meets with Prime Minister of the United Kingdom Sir Keir Starmer

OTTAWA, ON, June 15, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Prime Minister of the United Kingdom (UK), Sir...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Over 2000 Canadians take a big step for breakthroughs in cancer research and raise over $1.75 Million in support of The Princess Margaret

Participants of all ages come together to create a world free from the fear of cancer TORONTO, June 15, 2025 /CNW/ - Participants of all...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers